Open AccessClinical and cost–effectiveness of insulin degludec: from clinical trials to clinical practice
Author(s) -
Marc Evans,
Phil McEwan
Publication year - 2015
Publication title -
journal of comparative effectiveness research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.567
H-Index - 23
eISSN - 2042-6313
pISSN - 2042-6305
DOI - 10.2217/cer.15.10
Subject(s) - insulin degludec , medicine , glycemic , intensive care medicine , diabetes mellitus , clinical trial , insulin , cost effectiveness , basal insulin , health care , type 2 diabetes , endocrinology , risk analysis (engineering) , economic growth , economics
The increasing prevalence of diabetes presents one of the greatest challenges to healthcare provision in modern times, with the cost of treating diabetes and its related complications representing a significant proportion of healthcare expenditure. In recent years, many new therapeutic entities have been developed with the aim of improving glycemic control, and thus slowing the development of micro- and macrovascular complications. Insulin degludec is a new-generation basal insulin analog with an ultra-long duration of action and low day-to-day and hour-to-hour intrapatient variability in blood glucose-lowering action. In this review, we consider evidence from clinical trials and real-world studies demonstrating the clinical benefits and cost–effectiveness of insulin degludec and its potential for improving patient care.